US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 
• By Bridget Silverman
  
The novel agents second half goal dates will take the FDA down different roads than the first half approvals. (Shutterstock)

More from User Fee Goal Dates

More from US FDA Performance Tracker